Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
Date:1/31/2008

ATLANTA, Jan. 31 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that fourth quarter and year end 2007 financial results will be released on Thursday, February 21, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 21, 2008, to discuss the results followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available February 21 through February 28, 2008 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 271923.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife Web site at http://www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Communit
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
2. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
3. CryoLife Announces Record Preservation Services and Product Revenues for 2007
4. CryoLife to Present at OneMedPlace Finance Forum
5. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
6. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
7. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. GeoPharma Announces Third Quarter Conference Call

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)..., OMAHA, Neb., Nov. 5 T... announced financial results for the quarter ended...ts are presented in the tables that follow. ,, ...net loss of $366,000 or $0.01 per share for the th...499,000 or $0.01 per share for the third quarter o...
(Date:11/5/2009)..., FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ ...WGBS), a leading developer of state-of-the-art gen...opher Sears, Ph.D. has joined the company,s Scient...on designing and commercializing novel molecular d...ions, and on the development of computational biol...
(Date:11/5/2009)... Brooke Sanders brings a new...ne, CA (PRWEB) November 5, 2009 -- Professional Re... reprographics company is pleased to present Brook... as their graphics/PR specialist. The addition of ...sistent growth within Professional Reprographics.,...
(Date:11/4/2009)..., ,, ROCKVILLE, Md., Nov. 4 /PRNewswire/ -... company focused on next-generation antibody drug ...10 million in Series A funding from New Enterprise...ure capital firms. The capital will be used to cre...that address two or more biological targets with a...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
...y insiders knowingly misrepresented the .... 18 Hagens Berman Sobol Shapiro filed a,proposed...cs Corporation,(OTC Bulletin Board: CCYG) sharehol...esented the company and chief executive officer Ga...be traded at artificially,inflated prices., The l...
... and Company,strongly objects to implications in a...e company has suppressed results of negative clini...le in The New England Journal of,Medicine (NEJM), ... how the,industry purportedly suppresses negative ... inaccurate when it comes to Prozac -- the NEJM ar...
...utics Corporation today,announced the appointment ...Alliance Management. In this role, Ms. Perrow will...opment strategy and program execution through,prod...l also serve as a,member of Alba,s executive manag...nnounce that Ms. Perrow is joining Alba in,this cr...
Other Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management 2
(Date:11/4/2009)...D, Calif., Oct. 23 GenVault Corpor... management for genomic discovery, medicine and id...h.D., GenVault,s President and CEO, will be presen...e on October 26th and 27th in La Jolla, CA. ,, ...n overview of the company together with recent cus...
(Date:11/4/2009)...K, Oct. 27 Global Rainmakers, Inc....anced R&D laboratory, today announced that the...ared to actively commercialize its suite of techno... security offerings. ,, During the past four ye...lars to develop and deploy a series of core--but e...
(Date:11/4/2009)...D, Calif., Nov. 4 GenVault Corpora...rody, M.D., Ph.D., has joined its Board of Directo...r of the Salk Institute, is an acclaimed physician...g the Salk Institute, Dr. Brody served as presiden... of the National Academy of Engineering and the In...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 2Five Questions About Protopic 28tacrolimus 29 Ointment 13332 3Five Questions About Protopic 28tacrolimus 29 Ointment 13332 4Synthetic biology opportunities and risks 53488 1Synthetic biology opportunities and risks 53488 2Synthetic biology opportunities and risks 53488 3
...ed to exploring ways to broaden the use of clean, ...y 1 at Stanford University. , Energy Crossroads, ...ms to reduce society,s dependence on fossil fuels,...ion: Sparking Global Change." , Cathy Zoi, chief ...ection, a nonprofit organization founded by former...
...gist Stephan B. Poulter demonstrates in THE MOTHER... YOUR LIFE (Prometheus Books, $18.95) that most of...ted by our mothers or its far-reaching impact on o... the foundation from which our emotional developme...ve through adulthood. No other relationship in ou...
...ollaborative effort, researchers from Boston Unive...at deletions or mutations within the TFAP2A gene (... distinctive clefting disorder Branchio-Oculo-Faci...erized by specific skin anomalies involving the ne...l facial appearance, and frequently cleft lip and ...
Other Biology News:How your mother's emotional legacy impacts your life 2
... SYBR Green, TaqMan, LNA spiked TaqMan, MethyLight...specific primers are designed by avoiding cross ho... search results. Primer efficiency is enhanced by ...by connecting to the Mfold server. Beacon Designer...
Goat Anti-Human IL-17D Polyclonal Antibody, Unconjugated from R&D Systems
...-ADP, FHS-LVF and CVD-Diffuse We've combined our ...lters to create the world's first notch filter wit...andpass. Each filter features an excellent transmi...e filters -- with interference coatings applied to...
Agar - ULTRAPURE from GE Healthcare, formerly Amersham Biosciences
Biology Products: